Noninferiority study evaluating dexamethasone (DEX)-sparing regimens administered with NEPA, a fixed combination of netupitant and palonosetron, for the prevention of chemotherapy-induced nausea and vomiting (CINV) caused by high-dose cisplatin.

被引：0
|
作者：
Celio, Luigi
Bonizzoni, Erminio
Bria, Emilio
机构：
[1] Desenzano Garda Hosp, Oncol Unit, ASST Garda, Brescia, Italy
[2] Univ Milan, Fac Med & Surg, Sect Med Stat Biometry & Epidemiol GA Maccacaro, Dept Clin Sci & Commun, Milan, Italy
[3] Univ Cattolica Sacro Cuore, IRCCS, Fdn Policlin Univ Agostino Gemelli, Med Oncol,Comprehens Canc Ctr, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.12093
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
12093
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Fixed Combination Antiemetic A literature review on prevention of chemotherapy-induced nausea and vomiting using netupitant/palonosetron
    Clark-Snow, Rebecca A.
    Vidall, Cheryl
    Bojeson, Sussanne
    Jahn, Patrick
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2018, 22 (02) : E52 - E63
  • [22] NEPA, a fixed-dose combination of netupitant and palonosetron, prevents chemotherapy-induced nausea and vomiting (CINV) more effectively and reduces the impact on daily living for breast cancer patients compared with palonosetron
    Rugo, H. S.
    Rossi, G.
    Rizzi, G.
    Borroni, M. E.
    Lorusso, V.
    Karthaus, M.
    Bondarenko, I.
    Sarosiek, T. J.
    Aapro, M. S.
    CANCER RESEARCH, 2013, 73
  • [23] Palonosetron (PALO), administered orally or intravenously (IV), plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting (CINV)
    Boccia, R. V.
    Gonzalez, E. F.
    Pluzanska, A. G.
    Clerici, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study
    Luigi Celio
    Diego Cortinovis
    Alessio Aligi Cogoni
    Luigi Cavanna
    Olga Martelli
    Simona Carnio
    Elena Collovà
    Federica Bertolini
    Fausto Petrelli
    Alessandra Cassano
    Rita Chiari
    Francesca Zanelli
    Salvatore Pisconti
    Isabella Vittimberga
    Antonietta Letizia
    Andrea Misino
    Angela Gernone
    Erminio Bonizzoni
    Sara Pilotto
    Sabino De Placido
    Emilio Bria
    BMC Cancer, 22
  • [25] Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study
    Celio, Luigi
    Cortinovis, Diego
    Cogoni, Alessio Aligi
    Cavanna, Luigi
    Martelli, Olga
    Carnio, Simona
    Collova, Elena
    Bertolini, Federica
    Petrelli, Fausto
    Cassano, Alessandra
    Chiari, Rita
    Zanelli, Francesca
    Pisconti, Salvatore
    Vittimberga, Isabella
    Letizia, Antonietta
    Misino, Andrea
    Gernone, Angela
    Bonizzoni, Erminio
    Pilotto, Sara
    De Placido, Sabino
    Bria, Emilio
    BMC CANCER, 2022, 22 (01)
  • [26] Assessing the benefit of NEPA (fixed combination of netupitant/palonosetron) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients at increased emetic risk receiving moderately emetogenic chemotherapy
    Molasiotis, A.
    Aapro, M. S.
    Alonzi, A.
    Chrapava, M.
    Jordan, K.
    Roeland, E. J.
    Schwartzberg, L. S.
    Terrasanta, C.
    Olivari, S.
    Dranitsaris, G.
    ANNALS OF ONCOLOGY, 2022, 33 : 1546 - 1546
  • [27] Assessing the Benefit of NEPA (Fixed Combination of Netupitant/Palonosetron) for preventing Chemotherapy-induced Nausea and Vomiting (CINV) in patients at increased emetic risk receiving moderately emetogenic chemotherapy
    Karthaus, M.
    Christoph, D. C.
    Lux, M. P.
    Hofheinz, R. -D
    Jordan, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 252 - 253
  • [28] Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective
    Nilsson, Jonas
    Piovesana, Vittoria
    Turini, Marco
    Lezzi, Claudio
    Eriksson, Jennifer
    Aapro, Matti
    SUPPORTIVE CARE IN CANCER, 2022, 30 (11) : 9307 - 9315
  • [29] Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective
    Jonas Nilsson
    Vittoria Piovesana
    Marco Turini
    Claudio Lezzi
    Jennifer Eriksson
    Matti Aapro
    Supportive Care in Cancer, 2022, 30 : 9307 - 9315
  • [30] A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)
    Zhang, L.
    Lu, S.
    Feng, J.
    Dechaphunkul, A.
    Chang, J.
    Wang, D.
    Chessari, S.
    Lanzarotti, C.
    Jordan, K.
    Aapro, M.
    ANNALS OF ONCOLOGY, 2018, 29 (02) : 452 - 458
12345